abstract |
Antibodies that block the binding of human programmed killing receptor 1 (hPD-1) to the ligand (hPD-L1 or hPD-L2), and variable region sequences thereof, are described. Also described are methods of increasing the activity of the immune response (or reducing downregulation) through the PD-1 pathway. |